Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $6.50 USD
Change Today +0.10 / 1.56%
Volume 30.6K
VCYT On Other Exchanges
As of 8:10 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

veracyte inc (VCYT) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/24/15 - $12.47
52 Week Low
09/30/15 - $4.59
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VERACYTE INC (VCYT)

Related News

No related news articles were found.

veracyte inc (VCYT) Related Businessweek News

No Related Businessweek News Found

veracyte inc (VCYT) Details

Veracyte, Inc. operates as a molecular diagnostics company in the United States. It operates in the field of molecular cytology with genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early stage in patient care. The company offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers, which comprise the genomic tests for medullary thyroid cancer and BRAF V600E mutation status. It also develops a product to preoperatively identify idiopathic pulmonary fibrosis among patients presenting with a suspected interstitial lung disease; and the Percepta Bronchial Genomic Classifier, a lung cancer test that would identify patients with non-diagnostic bronchoscopy results whose nodules are at low risk of being cancerous. Veracyte, Inc. serves endocrinologists; radiologists; and ear, nose, and throat physicians. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

167 Employees
Last Reported Date: 03/25/15
Founded in 2006

veracyte inc (VCYT) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $425.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $300.0K
Chief Operating Officer
Total Annual Compensation: $341.2K
Compensation as of Fiscal Year 2014.

veracyte inc (VCYT) Key Developments

Veracyte, Inc. Announces Presentation of Percepta™ Bronchial Genomic Classifier Clinical Validation Data at the 16th World Conference on Lung Cancer

Veracyte, Inc. announced presentation of data supporting the use of the Percepta Bronchial Genomic Classifier to help reduce unnecessary, invasive biopsies as part of lung cancer diagnosis. The findings will be presented at the 16th World Conference on Lung Cancer, being held in Denver, Colo., September 6-9, 2015. The multicenter study involved 163 current or former smokers who were undergoing bronchoscopy to evaluate lung nodules or lesions that were suspicious for cancer. Among the 123 patients whose bronchoscopy results were inconclusive ‘meaning that cancer could not be ruled out’ the Percepta test identified patients at low risk of cancer with a high level of accuracy (negative predictive value of 94%). The genomic test and bronchoscopy had a combined ability to detect cancer (i.e., sensitivity) of 96%, compared to 51% for bronchoscopy alone. The findings being presented appeared previously in a journal article describing the Percepta test's development. Through this study, along with the AEGIS I and II trials, the Percepta test has been validated on more than 1,000 patients at over 30 medical centers. The Percepta Bronchial Genomic Classifier is designed to identify patients with lung nodules who are at low risk of cancer following an inconclusive bronchoscopy result, to enable these patients to be safely monitored with CT scans in lieu of invasive diagnostic procedures. The 23-gene molecular classifier uses proprietary genomic technology to detect molecular changes that occur in the epithelial cells lining the lung's respiratory tract in current or former smokers with lung cancer. These changes can be detected in cells obtained from standard cytology brushings taken during bronchoscopy from the mainstem bronchus and indicate the presence of malignancy or disease processes from distant sites in the lung. Thus, the test is designed to determine a lung nodule's or lesion's likelihood of cancer, without the need to sample the nodule or lesion directly. The Percepta test is performed at Veracyte'sCLIA-certified laboratory in South San Francisco, Calif. The company began making the Percepta classifier available to a limited number of institutions around the United States in April 2015.

Veracyte, Inc. Appoints Dr. Neil M. Barth as Chief Medical Officer

Veracyte, Inc. announced the appointment of Neil M. Barth, M.D., F.A.C.P., as chief medical officer, effective immediately. Dr. Barth has more than 30 years of experience providing and directing patient care for healthcare-provider organizations and diagnostics companies. Most recently, he served as chief medical officer for Agendia NV. Prior to that, Dr. Barth served as chief medical officer for Ambry Genetics.

Veracyte, Inc. Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-16-2015 10:30 AM

Veracyte, Inc. Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-16-2015 10:30 AM. Venue: The Grand Hyatt New York, 109 East 42nd Street, New York, New York, United States. Speakers: Bonnie H. Anderson, Co-Founder, Chief Executive Officer, President, Director and Member of Non-Management Equity Award Committee.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VCYT:US $6.50 USD +0.10

VCYT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Exact Sciences Corp $8.51 USD +0.71
Foundation Medicine Inc $19.97 USD +0.38
PDI Inc $1.75 USD -0.04
Rosetta Genomics Ltd $2.58 USD +0.0548
Trovagene Inc $5.72 USD +0.11
View Industry Companies

Industry Analysis


Industry Average

Valuation VCYT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.7x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERACYTE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at